Gastric Carcinoids: Prevalence in Europe and USA, and Rationale for Treatment with YF476, a Gastrin Receptor Antagonist

#427

Introduction: Gastric carcinoids (GC) are tumors arising from enterochromaffin-like (ECL) cells in the gastric mucosa. Most are caused by hypergastrinaemia, which stimulates ECL-cell growth. YF476 is a potent, selective and orally active gastrin receptor antagonist in humans in vitro and in vivo. YF476 prevented and caused shrinkage of GC in animal models of the condition.

Aim(s): To find out if prevalence of GC in Europe and USA meets the criteria for an orphan disease; whether the drug regulatory authorities in those areas would accept YF476 as an orphan medicinal product (OMP) for GC treatment; and if the prevalence of GC is increasing.

Materials and methods: We searched Pubmed, the USA National Cancer Institute’s SEER program and the National Cancer Registry for England, and contacted 100 European cancer registries.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Boyce M,

Keywords: gastric carcinoids, ECL cells, YF476, OMP,